Co-founders Da Hongfei and Erik Zhang have conflicting restructuring plans, Da wants independent governance and multi-sig protection; Zhang wants accountability investigations and to remain on the board.Finance, On-chain Data, NewsRead More

You might also be interested in reading AstraZeneca is said to seek approval for antihypertensive this year.